EN DE
Watch PT Hetzer Medical Indonesia Tb for free: we tell you when fair value or trend changes.
Data-driven stock valuation

PT Hetzer Medical Indonesia Tb (MEDS) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of PT Hetzer Medical Indonesia Tb stock IDR 50, price IDR 58, that is 13.9% below the price, quality 39 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare ID

PH PT Hetzer Medical Indonesia Tb logo Thin data Nov 10, 2026

PT Hetzer Medical Indonesia Tb

MEDS · JK
Expensive, weak quality

Our calculation puts a fair price 14% below what the stock costs today.

Low debt
Fair value 49.94 IDR · Overvalued
Quality 39/100
Weak Growth (revenue 5y −40.4 %/yr in IDR)
Loss-making · -2.8% net margin (TTM)
Negative free cash flow
Trails peers (3/11)
Narrow moat 25/100 · thin data
Thin data
Estimate
Watch PT Hetzer Medical Indonesia Tb for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

476.00 IDR 50.00 IDR Fair Value 49.94 IDR Aug 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

51‑month range 50.00 IDR – 476.00 IDR · fair‑value band 37.45 IDR – 62.42 IDR · the 58.00 IDR price screens above the 49.94 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow PT Hetzer Medical Indonesia Tb in your weekly email

Every Wednesday you see whether PT Hetzer Medical Indonesia Tb is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PT Hetzer Medical Indonesia Tbk manufactures and sells 4D masks in Indonesia. It offers stethoscopes, bouffant caps, face masks, and tensiometer. The company was founded in 2010 and is based in Cimahi, Indonesia.

Stock analysis

PT Hetzer Medical Indonesia Tb (MEDS) currently trades at 58.00 IDR, while our estimate is 49.94 IDR, 14% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 37.45 IDR (bear) to 62.42 IDR (bull), the price of 58.00 IDR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

PT Hetzer Medical Indonesia Tb reported revenue of 6.6B IDR in FY2025 versus 75.8B IDR in FY2021, a compound −45.6%/yr. Reported net income was −8.3B IDR in FY2025.

Key figures

Market cap 90.6B IDR (≈ $5.0M) Micro · P/S ratio 3.84 · Net margin −2.8% · Return on equity −1.3% · Return on assets (EBIT) 8.8% (5-year average) · Operating margin 20.7% · Revenue growth (YoY) +456% · EPS growth (YoY) −83.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).

What moves the price

The share trades about 58% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −14%, MEDS screens cheaper than that median.

Fair Value

Bear 37.45 IDR Fair Value 49.94 IDR Bull 62.42 IDR
Price 58.00 IDR · Downside -13.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 37
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 74
Debt, balance sheet and risk of trouble
Investment 69
Does it invest with discipline instead of growing at any price?
Low Volatility 24
How calm the share price moves, does not count
Price momentum 24
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 15
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+3.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−44.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−40.4%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
55.4% (2020) → −124.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

MEDS screens overvalued: fair value 14% below the price. Compare with Intuitive Surgical, Inc →

Compare PT Hetzer Medical Indonesia Tb with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 196 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Bottom 25%
Fair Value upside −13.9% · Below median
Profitability
Return on assets −13.5% · Bottom 25%
Net margin (12 months) −2.8% · Bottom 25%
Operating margin (12 months) 20.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 456.4% · Top 25%
Balance sheet
Debt / equity 0.16× · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 1.88× · Cheaper than median
P/S (12 months) 3.90× · Pricier than median
EV/EBITDA 28.6× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)15 · sector 21
FUTURE (revenue growth)100 · sector 40
PAST (return on equity)0 · sector 26
HEALTH (low debt)92 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.08 $131.27 +46% vs MEDS
EssilorLuxottica Société anonyme EL €187.60 €196.22 +5% vs MEDS
Intuitive Surgical, Inc ISRG $450.04 $353.90 −21% vs MEDS
Medline Inc MDLN $40.91 $28.59 −30% vs MEDS
Alcon Inc ALC CHF 61.88 CHF 34.06 −45% vs MEDS
Becton, Dickinson and Company BDX $212.61 $97.80 −54% vs MEDS
Straumann Holding STMN CHF 106.85 CHF 45.50 −57% vs MEDS
West Pharmaceutical Services, Inc WST $412.55 $139.22 −66% vs MEDS
Sartorius Stedim Biotech S.A DIM €223.40 €54.82 −75% vs MEDS
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs MEDS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PT Hetzer Medical Indonesia Tb: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "PT Hetzer Medical Indonesia Tb Fair Value". https://www.fairvalue-calculator.com/stock/MEDS.JK

Frequently asked questions

Is PT Hetzer Medical Indonesia Tb (MEDS) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 49.94 IDR versus a price of 58.00 IDR, about 14% lower (overvalued).
What is the fair value of MEDS?
Our estimate for PT Hetzer Medical Indonesia Tb is 49.94 IDR (as of Nov 10, 2026), built from audited fundamentals. The current price: 58.00 IDR.
What is the quality score of MEDS?
PT Hetzer Medical Indonesia Tb has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PT Hetzer Medical Indonesia Tb (MEDS)?
Our calculated price target is the estimate of 49.94 IDR (as of Nov 10, 2026). Cautious scenario 37.45 IDR, optimistic scenario 62.42 IDR. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the PT Hetzer Medical Indonesia Tb stock forecast for 2026?
Our estimate puts fair value at 49.94 IDR, about 14% lower versus a price of 58.00 IDR (overvalued). Cautious scenario 37.45 IDR, optimistic scenario 62.42 IDR. The calculation is refreshed regularly with new filings.
What is the intrinsic value of PT Hetzer Medical Indonesia Tb (MEDS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PT Hetzer Medical Indonesia Tb it is 49.94 IDR per share (as of Nov 10, 2026), against a price of 58.00 IDR.
Is PT Hetzer Medical Indonesia Tb stock overvalued or undervalued in 2026?
As of Nov 10, 2026, MEDS trades above its calculated fair value: price 58.00 IDR, fair value 49.94 IDR, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MEDS?
No. The price is what the market pays today (58.00 IDR); the fair value is what the company's own numbers justify (49.94 IDR). For PT Hetzer Medical Indonesia Tb the two are 8.06 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is PT Hetzer Medical Indonesia Tb worth?
The market values PT Hetzer Medical Indonesia Tb at about 90.6B IDR (market capitalisation, as of Nov 10, 2026). Per share that is 58.00 IDR; our models calculate a fair value of 49.94 IDR per share.
What do the bullish and bearish scenarios say about MEDS?
Our models span a range for PT Hetzer Medical Indonesia Tb: cautious scenario 37.45 IDR, base 49.94 IDR, optimistic 62.42 IDR per share (as of Nov 10, 2026, price 58.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PT Hetzer Medical Indonesia Tb (MEDS)?
Balance-sheet figures for PT Hetzer Medical Indonesia Tb (as of Nov 10, 2026): return on equity −1.3%, debt of 0.16 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is MEDS from its 52-week high?
PT Hetzer Medical Indonesia Tb trades at 58.00 IDR, about 58% below its 52-week high of 138.00 IDR and 5% above the low of 55.00 IDR (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 49.94 IDR is for.
Which stocks are comparable to PT Hetzer Medical Indonesia Tb?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PT Hetzer Medical Indonesia Tb stock attractive at the current price?
The data as of Nov 10, 2026: price 58.00 IDR, calculated fair value 49.94 IDR (−14%), Quality Score 39/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. PT Hetzer Medical Indonesia Tb itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PT Hetzer Medical Indonesia Tb (MEDS)?
The closing price on Nov 10, 2026 was 58.00 IDR. Our estimate is 49.94 IDR, about 14% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PT Hetzer Medical Indonesia Tb right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of PT Hetzer Medical Indonesia Tb

How large is the market capitalisation of PT Hetzer Medical Indonesia Tb (MEDS)?
The market capitalisation of PT Hetzer Medical Indonesia Tb is 90.6B IDR (≈ $5.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PT Hetzer Medical Indonesia Tb (MEDS)?
The price-to-sales ratio of PT Hetzer Medical Indonesia Tb is 3.84 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of PT Hetzer Medical Indonesia Tb (MEDS)?
The net margin of PT Hetzer Medical Indonesia Tb is −2.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PT Hetzer Medical Indonesia Tb (MEDS)?
The return on equity (ROE) of PT Hetzer Medical Indonesia Tb is −1.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PT Hetzer Medical Indonesia Tb (MEDS)?
On an EBIT basis the return on assets of PT Hetzer Medical Indonesia Tb is 8.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PT Hetzer Medical Indonesia Tb (MEDS)?
The operating margin of PT Hetzer Medical Indonesia Tb is 20.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PT Hetzer Medical Indonesia Tb (MEDS)?
Revenue at PT Hetzer Medical Indonesia Tb is growing +456% versus a year earlier (3y avg −44.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PT Hetzer Medical Indonesia Tb (MEDS)?
Earnings per share at PT Hetzer Medical Indonesia Tb are growing −83.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does PT Hetzer Medical Indonesia Tb (MEDS) generate?
The free cash flow of PT Hetzer Medical Indonesia Tb is −2.7B IDR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does PT Hetzer Medical Indonesia Tb (MEDS) carry?
The net debt of PT Hetzer Medical Indonesia Tb is 7.2B IDR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch PT Hetzer Medical Indonesia Tb in the live analysis

One click puts PT Hetzer Medical Indonesia Tb on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.